Success Story: Overcoming RFE: Indian Fellow Physician Secures NIW Approval with Our Strategy and Premium Processing
Client’s Testimonial:
“Thank you so much. I really appreciate your timely response, thorough, detailed work, and experience. Your patience and dedication during case preparation and RFE response made this process a success. I am thankful to all the team for the hard work, special thanks to Medessa and William B for the RFE response and initial case preparation. Your hard work, devotion, and expertise made this approval possible.”
On April 7th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Fellow Physician in the Field of Surgery (Approval Notice).
General Field: Surgery
Position at the Time of Case Filing: Fellow Physician
Country of Origin: India
State of Residence at the Time of Filing: Virginia
Approval Notice Date: April 7th, 2025
Processing Time: 6 months, 25 days (Premium Processing Requested)
Case Summary:
We’re pleased to share the successful I-140 National Interest Waiver (NIW) approval of a highly accomplished MBBS holder, whose work in transplant surgery is making critical contributions to the development of equitable and effective liver transplant policies in the United States.
This expert’s research centers on developing novel allocation models that assess the impact of recent liver transplant policy changes. Her work helps shape national guidelines aimed at reducing the burden of liver disease and improving patient outcomes. Through her clinical and academic role in the U.S., she actively leads transplant teams and performs complex procedures while contributing scholarly work to the field of surgical oncology and hepatology.
To support her NIW petition, we demonstrated her qualifications through:
● 2 peer-reviewed journal articles and 5 abstracts published in top-tier journals;
● A citation count of 120, with several works referenced by other leading researchers;
● Evidence of her peer-reviewed contributions and impactful research in major medical publications.
Her research has been cited in high-impact studies involving the molecular and imaging-based classification of liver tumors, as well as in evaluations of surgical strategies for hepatic adenomas. We emphasized that her work not only addresses a significant public health issue affecting millions of U.S. citizens and costing the healthcare system billions annually, but also drives practical improvements in clinical care.
Following the submission of a strong petition and response to an RFE, USCIS approved the case under premium processing after 6 months and 25 days, affirming that her continued research serves the national interest.
We commend this dedicated physician on her achievement and look forward to her ongoing contributions to liver disease treatment and transplant policy optimization.